Valeant may put its big-name eye-surgery equipment business on the block as part of a sweeping effort to unload assets and pare debt, WSJ.com reported, citing sources.

The business, which the Canadian drugmaker acquired with its purchase of Bausch & Lomb, could fetch as much as $2.5 billion, sources said.

The sales process is in an early stage, WSJ.com reported, and Valeant may still decide not to sell the business.